News & Updates

Consolidation treatment with the PD-L1 antibody durvalumab following concurrent chemoradiotherapy significantly prolonged overall (OS) and progression-free survival (PFS) in patients with limited-stage small-cell lung cancer (SCLC), as shown in the interim analysis of the phase III ADRIATIC trial.

Use of neoadjuvant daromun in addition to surgery is safe and provides survival benefits in patients with resectable, locally advanced melanoma, results of the PIVOTAL study have shown.

Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.

Patients with inflammatory bowel disease (IBD) who use statins appear to have a substantially reduced risk of primary sclerosing cholangitis (PSC), as shown in a retrospective study.

The intermittent 48-h “gap” schedule of olaparib in combination with carboplatin/paclitaxel and anthracycline chemotherapy provides substantial survival benefits in patients with germline BRCA-mutated breast cancer (gBRCA) regardless of their pathological complete response (pCR) status, results of the PARTNER trial have shown.

A handheld, 6-lead electrocardiographic (ECG) device may be an effective triage test that could reduce the need for 12-lead ECG monitoring in resource-limited, rifampin-resistant tuberculosis (RR-TB) treatment settings, according to a diagnostic prospective cohort study.

Adding the PD-1/CTLA-4 bispecific antibody cadonilimab to chemotherapy improves overall survival (OS) and progression-free survival (PFS) in individuals with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer, including patients with PD-L1–low tumours, according to the interim results of the phase III COMPASSION-15 trial.